ADVFN - Advanced Financial Network.
HOME» NASDAQ » Z » ZGEN Stock Price » ZGEN Stock News

Zymogenetics Share News

 Zymogenetics (mm) Stock Price
ZGEN Stock Price
 Zymogenetics (mm) Stock Chart
ZGEN Stock Chart
 Zymogenetics (mm) Stock News
ZGEN Stock News
 Zymogenetics (mm) Company Information
ZGEN Company Information
 Zymogenetics (mm) Stock Trades
ZGEN Stock Trades

ZymoGenetics Reports "Positive" Results In Melanoma Study

DOW JONES NEWSWIRES ZymoGenetics Inc. (ZGEN) said an experimental immunotherapy treatment for metastatic melanoma showed "positive survival" results in a mid-stage trial. The data come in the midst of Bristol-Myers Squibb Co.'s (BMY) $836 million buyout of ZymoGenetics. Chief Executive Lamberto Andreotti has said the acquisition would strengthen its Hepatitis C portfolio. In the study of 40 patients with advanced melanoma, participants were treated with one of three doses of the drug. The median overall survival rate was 12.4 months, with 53% surviving after a year. Overall response rate was 23% in evaluable patients, and progression-free survival was 4.3 months. Common adverse effects were fatigue, rash, fever myalgia, anorexia, chills and nausea. Among ZymoGenetics other products are Recothrom, a drug used in surgeries to prevent blood clotting, and six biologic drug candidates for atopic dermatitis. ZymoGenetics shares closed Tuesday at $9.75--the buyout price--and were inactive premarket. -By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; [email protected]

Stock News for Zymogenetics (ZGEN)
No Recent News Available

Zymogenetics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations